Showing 1416 results
-
Story /Novartis researchers are peering deep inside knees to see if regenerated cartilage is springy like natural cartilage.
-
Story /Novartis is taming nuclear power and putting it to use to treat advanced cancer.
-
Press release /Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other…
-
Press release /Approval based on landmark PARADIGMS study showing Gilenya (fingolimod) significantly reduced relapse rates by 82% vs interferon beta-1a; additionally, 85.7% of Gilenya patients were relapse-free…
-
Story /Research exploring the first visible changes in the brain is helping scientists evaluate new potential treatments for Alzheimer’s.
-
Story /From curiosity about life on Earth to transformative therapies at Novartis. Michelle L Krishnan, Executive Director, MD PhD.
-
Press release /Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire…
-
Press release /Biosimilar HyrimozTM (adalimumab-adaz) approved for all indications of reference medicine not protected by orphan exclusivity **Biosimilars are critical to sustaining US healthcare system, providing…
-
Press release /Subject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…
-
Press release /If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…